BeiGene, Ltd.

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
130.9 ^USD	+1.10%		-5.39%	-27.40%

12:00pm	BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	CI
Apr. 17	BeiGene to Award Shares Worth $15 Million to 11 Directors	MT

Beigene, Ltd. Appoints Julia Wang Chief Financial Officer, Effective June 30, 2021

May 06, 2021 at 06:03 pm EDT

BeiGene, Ltd. Announced that Julia Wang has been appointed Chief Financial Officer, effective June 30, 2021.

Latest news about BeiGene, Ltd.

BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	06:00am	CI
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10	MT
Beigene Shrinks Loss by 56% in 2023	Mar. 29	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	Mar. 27	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
BeiGene, Ltd. Announces Executive Changes	Mar. 20	CI
Beigene's Esophageal Cancer Drug Gets US FDA Nod	Mar. 15	MT
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing	Mar. 14	MT
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients	Mar. 14	DJ
BeiGene Gets FDA Approval for Esophageal Cancer Treatment	Mar. 14	MT
BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	Mar. 14	CI
US FDA approves BeiGene's esophageal cancer therapy	Mar. 14	RE
BeiGene Sells Over 1 Million Underlying Shares Under Purchase Plan	Mar. 14	MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	Mar. 13	MT
BeiGene, Max Foundation Providing Brukinsa to Leukemia Patients in Armenia, Nepal as Part of 3-Year Partnership	Mar. 13	MT
BeiGene Shares Rise on First Dosing of Brukinsa	Mar. 13	DJ
BeiGene Gets FDA's Accelerated Approval for Follicular Lymphoma Treatment	Mar. 07	MT
BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma	Mar. 07	CI
US FDA approves expanded use of BeiGene's blood cancer drug	Mar. 07	RE
BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024	Mar. 06	CI
BeiGene's Pi Health Units to Merge	Mar. 06	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	Feb. 29	MT

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BeiGene, Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

130.9 USD

Average target price

268.6 USD

Spread / Average Target

+105.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BEIGENE, LTD.	-27.40%	13.68B
REGENERON PHARMACEUTICALS, INC.	+2.49%	96.73B
ARGENX SE	-0.52%	21.31B
BIONTECH SE	-16.61%	21.21B
GENMAB A/S	-5.34%	18.79B
WUXI APPTEC CO., LTD.	-42.14%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+1.44%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.29%	10.98B
LEGEND BIOTECH CORPORATION	-21.79%	8.56B
ASCENDIS PHARMA A/S	+12.82%	8.12B

Bio Therapeutic Drugs

BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Beigene, Ltd. Appoints Julia Wang Chief Financial Officer, Effective June 30, 2021

Latest news about BeiGene, Ltd.

Chart BeiGene, Ltd.

Company Profile

Income Statement Evolution

Ratings for BeiGene, Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs